MediWound (NASDAQ:MDWD) Stock Rating Upgraded by Wall Street Zen

Key Points

• Wall Street Zen upgraded MediWound from “strong sell” to “sell,” but broader analyst sentiment remains more positive, with a consensus “Moderate Buy” rating and a $33 price target.
• MediWound shares opened at $13.84, near the lower end of their 52-week range of $12.52 to $20.03. The company reported a quarterly loss of $0.77 per share, slightly worse than estimates, although revenue of $3.09 million exceeded expectations.
• COO Shmuel Hess sold 3,958 shares for approximately $51,137, while institutional investors own 46.83% of the company’s stock.

MediWound (NASDAQ:MDWD - Get Free Report) was upgraded by Wall Street Zen from a "strong sell" rating to a "sell" rating in a research report issued to clients and investors on Saturday, Wall Street Zen reports.

A number of other equities analysts also recently weighed in on MDWD. Weiss Ratings downgraded shares of MediWound from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Tuesday, September 8th. Alliance Global Partners reissued a "buy" rating on shares of MediWound in a research report on Wednesday, September 16th. TD Cowen restated a "buy" rating on shares of MediWound in a research note on Thursday. Finally, Oppenheimer reaffirmed an "outperform" rating and issued a $30.00 target price (down from $32.00) on shares of MediWound in a research report on Friday, August 14th. Four investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $33.00.

MediWound Trading Up 0.1%

Shares of NASDAQ MDWD opened at $13.84 on Friday. MediWound has a one year low of $12.52 and a one year high of $20.03. The firm has a market capitalization of $177.84 million, a PE ratio of -7.69 and a beta of 0.14. The business has a 50-day moving average price of $13.66 and a two-hundred day moving average price of $15.07.

MediWound (NASDAQ:MDWD - Get Free Report) last issued its earnings results on Thursday, August 13th. The biopharmaceutical company reported ($0.77) earnings per share for the quarter, missing analysts' consensus estimates of ($0.76) by ($0.01). MediWound had a negative net margin of 170.10% and a negative return on equity of 47.24%. The business had revenue of $3.09 million during the quarter, compared to analyst estimates of $2.59 million. Research analysts anticipate that MediWound will post -2.37 EPS for the current year.

Insider Buying and Selling

In other MediWound news, COO Shmuel Hess sold 3,958 shares of the firm's stock in a transaction dated Thursday, August 27th. The stock was sold at an average price of $12.92, for a total transaction of $51,137.36. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 9.20% of the stock is owned by insiders.

Hedge Funds Weigh In On MediWound

An institutional investor recently raised its stake in MediWound stock. Clal Insurance Enterprises Holdings Ltd increased its position in MediWound Ltd. (NASDAQ:MDWD - Free Report) by 22.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 71,000 shares of the biopharmaceutical company's stock after acquiring an additional 13,196 shares during the quarter. Clal Insurance Enterprises Holdings Ltd owned about 0.55% of MediWound worth $1,311,000 at the end of the most recent quarter. Institutional investors and hedge funds own 46.83% of the company's stock.

MediWound Company Profile

MediWound Ltd. NASDAQ: MDWD is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative enzymatic therapies for tissue injury and wound care. The company's products are designed to remove damaged or nonviable tissue while helping preserve healthy tissue, supporting wound management and healing.

MediWound's lead commercial product is NexoBrid, a topical bromelain-based therapy used for the enzymatic removal of eschar in adults with deep partial-thickness and full-thickness thermal burns.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.